Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease.
about
Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an updateTherapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic diseaseNonsurgical treatment options in Peyronie's Disease: 2016 updateThe effect of mirodenafil on the penile erection and corpus cavernosum in the rat model of cavernosal nerve injury.Reversion of penile fibrosis: Current information and a new horizon.The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets.Treatment with a combination of ginger, L-citrulline, muira puama and Paullinia cupana can reverse the progression of corporal smooth muscle loss, fibrosis and veno-occlusive dysfunction in the aging rat.The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems.PDE5 inhibitors beyond erectile dysfunction.Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review.Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms.Penile rehabilitation following treatment for prostate cancer: an analysis of the current state of the art.Vardenafil increases cell proliferation in the dentate gyrus through enhancement of serotonin expression in the rat dorsal raphe.Current status and new developments in Peyronie's disease: medical, minimally invasive and surgical treatment options.Peyronie's disease: perspectives on therapeutic targets.Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors.Rat as an animal model for Peyronie's disease research: a review of current methods and the peer-reviewed literature.Daily dosing of PDE5 inhibitors: where does it fit in?Redox signaling as a therapeutic target to inhibit myofibroblast activation in degenerative fibrotic diseaseAdministration of Goji (Lycium chinense Mill.) Extracts Improves Erectile Function in Old Aged Rat Model.The Efficacy of Medical Treatment of Peyronie's Disease: Potassium Para-Aminobenzoate Monotherapy vs. Combination Therapy with Tamoxifen, L-Carnitine, and Phosphodiesterase Type 5 Inhibitor.Understanding the cellular basis and pathophysiology of Peyronie's disease to optimize treatment for erectile dysfunction.Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie's disease.Effectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie's disease: a study of 151 cases.Current and emerging treatment options for Peyronie's disease.Decorin as a new treatment alternative in Peyronie's disease: preliminary results in the rat model.Does penile rehabilitation have a role in the treatment of erectile dysfunction following radical prostatectomy?Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection.Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial.[Conservative therapy of Peyronie's disease - update 2015].Effect of vardenafil on nitric oxide synthase expression in the paraventricular nucleus of rats without sexual stimulation.All about Peyronie's disease.Erectile dysfunction
P2860
Q26775925-6CA6B2ED-1D66-4ECA-969E-7B54509BB75CQ26827629-5D505711-D25B-4354-BA0E-77FDCCE7CE3AQ28075809-69379F47-3992-48E2-ACA1-BB7E98D152B2Q34222425-B1DD5669-B8F2-4B14-831B-4387FC88072DQ34502071-739C0202-5F0C-4478-8A85-74B221C5CADAQ35116422-77A088CF-3BDC-4F04-8CDB-C9A287183434Q36082711-30B95C22-9704-4F81-B3C9-ACD08B902698Q36500200-8C90987E-EA93-4FF3-8602-07E01B4F1526Q36878017-2994BECF-C40E-469A-9C3F-E33F8BB8CE19Q36900830-3BD7B1B7-1B14-4FBD-AA5B-91B8331E246AQ37030511-88068CA9-2B2D-44F8-955C-85D82850275AQ37417114-362EDC8E-E086-4192-A1F1-AA819EB21E6AQ37417945-787602BC-ECCC-455B-BBC4-1A564567B8FEQ37853180-FDFC14B3-B929-4D23-989B-51BD4AB0BE79Q37865017-1732C3C5-FBA6-4FB7-9E2C-56E9C1A658A9Q37903037-ECCAA9FE-C9A1-4102-BCA8-C09D07B70726Q37903227-C2B9C72D-09F5-465D-BFAB-1476E33D337DQ38115198-818D60EC-E9CB-4183-8F6B-DF276639499CQ38202115-E52009AC-B5E0-4B4C-9371-76BE7B8B18BDQ38406941-FDCFCFED-0351-43DB-BB41-853C1A6CCECAQ38414602-6B5BA55F-066D-4158-9DBF-3008D6EDF064Q39143837-43945638-C057-432B-9631-2BB571D63EA1Q41863269-79949D12-01F5-4F44-B3FF-E9CDAE73589AQ41909374-C53C45E5-716F-4F88-84CB-8D68C5D5EEF4Q42908597-B77E325D-B4DF-4A42-AB80-7F3C20BE8051Q43601232-0DBA609D-F68F-4241-A90A-4CA894F52414Q45347452-27CB5266-2294-4275-9D50-BC418D7734DEQ46987652-D7A47C60-02B2-4089-8C45-8ECAEF0CA653Q48545304-072AD565-2B01-4E43-970A-645873842DFBQ48801672-1572EB83-A13C-42F3-A73F-18CB48354F21Q48877065-3A1353C0-1206-4149-AF02-EDD52AC846D2Q54957145-FFED1CBF-345F-49A0-9A82-401AD3C1576CQ56966121-06A615AD-CCAC-4967-A1D6-AEE5ED474F99
P2860
Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Effects of long-term vardenafi ...... t model of Peyronie's disease.
@en
Effects of long-term vardenafi ...... t model of Peyronie's disease.
@nl
type
label
Effects of long-term vardenafi ...... t model of Peyronie's disease.
@en
Effects of long-term vardenafi ...... t model of Peyronie's disease.
@nl
prefLabel
Effects of long-term vardenafi ...... t model of Peyronie's disease.
@en
Effects of long-term vardenafi ...... t model of Peyronie's disease.
@nl
P2093
P2860
P1433
P1476
Effects of long-term vardenafi ...... at model of Peyronie's disease
@en
P2093
Gaby Nolazco
Jacob Rajfer
Monica G Ferrini
Nestor F Gonzalez-Cadavid
P2860
P304
P356
10.1111/J.1464-410X.2006.05955.X
P577
2006-03-01T00:00:00Z